The US Cannabis Sector Is Nearing A Major Event

A major market-moving event for the US cannabis sector will arrive soon. We are referring to the upcoming administrative hearing to determine whether recreational marijuana will follow in the footsteps of medical marijuana and be moved from Schedule 1 to Schedule 3 under the Controlled Substances Act. The hearing will start on 29th June and finish no later than 15th July, potentially paving the way for a decision by the end of August. We expect the result to be positive, that is, we expect that recreational marijuana will be moved to Schedule 3, thus completely eliminating the excess federal taxation on state-legal cannabis sellers and propelling the associated stock prices to much higher levels. However, a positive outcome is not guaranteed.

The following weekly chart shows that the US Cannabis ETF (MSOS) gained more than 11% last week. Part of this gain would have been related to anticipation of a positive rescheduling decision, but the bulk of it was due to a surge in the price of a single stock: Trulieve Cannabis (TCNNF). The price of TCNNF, one of MSOS’s two largest holdings, rocketed upward late last week in reaction to news that it would soon up-list onto the NYSE. This means that Trulieve will be the first US cannabis company to list on a major US exchange.

Note that the TSI Stocks List has indirect exposure to TCNNF via MSOS.

Trulieve has achieved its up-listing by restructuring its business to separate medical sales from recreational sales. Other US cannabis companies could follow suit, but we expect that most of them will wait for the outcome of the above-mentioned hearing. The reason is that there will be no need to restructure in order to up-list if recreational cannabis is moved to Schedule 3.

We continue to expect that if cannabis is fully rescheduled, MSOS will rise quickly to the US$9-$10 area. In the meantime, resistance at US$6.00-$6.50 probably will limit the upside.